CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Vaxcyte Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Vaxcyte Inc
825 INDUSTRIAL ROAD, STE. 300
Phone: (302) 658-7581p:302 658-7581 SAN CARLOS, CA  94070  United States Ticker: PCVXPCVX
Business Summary
Vaxcyte, Inc. is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company's pipeline includes VAX-31, VAX-24 and VAX-XL. VAX-31, a 31-valent PCV candidate being evaluated in the OPUS Phase III adult clinical program and in a Phase II infant clinical program, is being developed for the prevention of IPD and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-XL leverages the Company’s carrier-sparing, site-specific conjugation technology. It is re-engineering the way highly complex vaccines are made through XpressCF, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202612/31/2025YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Carlos V.Paya 66 10/27/2021 10/27/2021
President, Chief Financial Officer Andrew L.Guggenhime 57 12/1/2020 5/1/2020
Chief Executive Officer, Co-Founder, Director Grant E.Pickering 57 12/1/2020 11/1/2013
7 additional Officers and Directors records available in full report.

Business Names
Business Name
PCVX
Vaxcyte Switzerland GmbH

General Information
Number of Employees: 507 (As of 12/31/2025)
Outstanding Shares: 144,397,682 (As of 5/4/2026)
Shareholders: 7
Stock Exchange: NASD
Federal Tax Id: 464233385
Fax Number: (302) 655-5049


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, May 13, 2026